Wells Fargo analyst Derek Archila upgraded Viridian Therapeutic (NASDAQ: VRDN) from Equal Weight to Overweight with a price target of $31.00.

For an analyst ratings summary and ratings history on Viridian Therapeutic click here. For more ratings news on Viridian Therapeutic click here.

Shares of Viridian Therapeutic closed at $17.90 yesterday.